Lineage Cell Therapeutics logo

Lineage Cell Therapeutics (LCTX) Q1 2025 Earnings

LCTX·Reported May 13, 2025·After market close

Lineage Cell Therapeutics reported Q1 2025 revenue of $1.5M (+4.0% YoY), missed analyst consensus of $1.7M by $222.3K. Diluted EPS came in at $-0.02 (+50.0% YoY).

Revenue
$1.5Mmissed by $222.3K
Consensus: $1.7M
Diluted EPS
$-0.02met estimate
Consensus: $-0.02
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-25-070378

Financial Snapshot

Trailing eight quarters through Q1 2025

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q1 2025 Earnings FAQ

Common questions about Lineage Cell Therapeutics's Q1 2025 earnings report.

Lineage Cell Therapeutics (LCTX) reported Q1 2025 earnings on May 13, 2025 after market close.

Lineage Cell Therapeutics reported revenue of $1.5M and diluted EPS of $-0.02 for Q1 2025.

Revenue missed the consensus estimate of $1.7M by $222.3K. EPS beat the consensus estimate of $-0.02 by $0.00.

Compared to the same quarter a year prior, revenue grew 4.0% from $1.4M a year earlier and diluted EPS grew 50.0% from $-0.04.

You can read the 10-Q periodic report (0000950170-25-070378) directly on SEC EDGAR. The filing index links above go to sec.gov.